首页> 外文OA文献 >First-Line Afatinib 30 Mg Daily and 40 Mg Daily Showed Similar Efficacy in Patients with Stage IV Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptormutation in Exon 19 or 21

【2h】

First-Line Afatinib 30 Mg Daily and 40 Mg Daily Showed Similar Efficacy in Patients with Stage IV Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptormutation in Exon 19 or 21

机译：第一线AFATINIB每日30毫克，每日40毫克每日表现出类似的患者IV阶段肺腺癌患者的疗效，其含有外显子19或21的表皮生长因子竞争力

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J.Y. Ma; C.-J. Yang; M.-J. Tsai; Y.-C. Chen; Y.-C. Tsai; M.-H. Lee; J.-Y. Hung; M.-S. Huang; I.-W. Chong;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN [J] . Yang Chih Jen, Tsai Ming-Ju, Hung Jen-Yu, Respirology : . 2018,第Suppla2期

机译：一线吉非替尼，厄洛替尼和Afatinib在患者中提供了类似的临床疗效，患者患有罕见的台湾罕见的EGFR突变
2. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors [J] . Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, Cancers . 2018,第11期

机译：一线酪氨酸激酶抑制剂治疗具有罕见表皮生长因子受体突变的Ⅳ期肺腺癌老年患者更好的无进展生存期
3. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation [J] . ParkS.J., KimH.T., LeeD.H., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第3期

机译：表皮生长因子受体酪氨酸激酶抑制剂对具有外显子19或21外显子突变的非小细胞肺癌患者脑转移的疗效
4. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations [O] . Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, 2017

机译：在具有外显子19或外显子21突变的IV期肺腺癌患者中每天30 mg阿法替尼作为起始剂量的临床疗效可能不逊于每天40 mg的阿法替尼
5. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations [O] . Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, 2017

机译：每天作为起始剂量的AFATINIB 30毫克的临床疗效可能不会低于IV阶段19或外显子21突变的阶段IV肺腺癌患者的AFATINIB 40mg

First-Line Afatinib 30 Mg Daily and 40 Mg Daily Showed Similar Efficacy in Patients with Stage IV Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptormutation in Exon 19 or 21

著录项

引文网络

相似文献

相关主题

期刊订阅